tradingkey.logo
tradingkey.logo
Search

Renovaro Inc

RENB
Add to Watchlist
1.420USD
0.0000.00%
Market hours ETQuotes delayed by 15 min
14.83MMarket Cap
LossP/E TTM

More Details of Renovaro Inc Company

Lunai Bioworks, Inc., formerly Renovaro Inc., is focused on AI-powered biodefense, drug discovery and advanced diagnostics. The Company is engaged in harnessing advanced computational biology and AI/machine learning to accelerate drug discovery, diagnostics and strengthen biosecurity capabilities. From high-resolution phenotyping to predictive disease modeling, the Company is pioneering a new era of precision diagnostics-where early detection, patient stratification, and therapeutic targeting converge into a single, adaptive platform. These are designed to transform clinical decision-making, reduce time-to-treatment, and unlock previously inaccessible insights from biological data. Its proprietary platforms in translational analytics, in vivo modeling, and machine vision-accelerating biomarker discovery and therapeutic development in precision neurology and infectious disease.

Renovaro Inc Info

Ticker SymbolRENB
Company nameLunai Bioworks Inc
IPO dateNov 18, 2014
CEOWeinstein (David)
Number of employees- -
Security typeOrdinary Share
Fiscal year-endNov 18
Address2080 Century Park East, Suite 906
CityLOS ANGELES
Stock exchangeNASDAQ Capital Market Consolidated
CountryUnited States of America
Postal code90067
Phone14539179840
Website
Ticker SymbolRENB
IPO dateNov 18, 2014
CEOWeinstein (David)

Company Executives of Renovaro Inc

Name
Name/Position
Position
Shareholding
Change
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--
Name
Name/Position
Position
Shareholding
Change
Mr. Douglas W. Calder
Mr. Douglas W. Calder
Independent Director
Independent Director
--
--
Mr. James A. Mcnulty, CPA
Mr. James A. Mcnulty, CPA
Independent Director
Independent Director
--
--
Mr. Mark Anthony Collins, Ph.D.
Mr. Mark Anthony Collins, Ph.D.
Independent Director
Independent Director
--
--
Mr. David Weinstein
Mr. David Weinstein
Chief Executive Officer, Director
Chief Executive Officer, Director
--
--
Mr. Chris Tyson
Mr. Chris Tyson
Executive Vice President - Investor Relations
Executive Vice President - Investor Relations
--
--
Mr. Nathen Fuentes, CPA
Mr. Nathen Fuentes, CPA
Chief Financial Officer
Chief Financial Officer
--
--

FAQs

Who are the top five shareholders of Renovaro Inc?

The top five shareholders of Renovaro Inc are: Mr. Douglas W. Calder

How many institutions hold shares of Renovaro Inc (RENB)?

As of 2026Q1, 139 institutions hold shares of Renovaro Inc, with a combined market value of approximately 1.10M, accounting for 3.04% of the total shares. Compared to 2025Q4, institutional shareholding has increased by -513101.00.